# Heidi Overton

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/heidi-overton
Canonical HTML page: https://getbiobrief.com/entity/heidi-overton

## Timeline

- **2026-08-19**: Trump announces Heidi Overton as FDA Commissioner nominee — President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.
- **2026-05**: Marty Makary resigns as FDA Commissioner — The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots.

## Recent coverage (2 stories)

### Overton FDA Nomination: 4 Biopharma Risks From Drug Pricing to Vaccines
2026-08-20 00:44:07 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

For biotech and pharma executives, Overton's nomination combines Trump's favored-nation drug pricing push with RFK Jr.'s vaccine skepticism and unfinished reviews of antidepressants and COVID shots. The result could compress margins while opening faster approval pathways for innovation. Investors should watch how she navigates evidence standards and political priorities at the FDA.
Full story: https://getbiobrief.com/story/overton-fda-biopharma-drug-pricing-vaccine-risks

### Trump's 3rd-Choice FDA Pick Overton Shifts Pharma's Regulatory Outlook
2026-08-19 18:17:37 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Biopharma's key regulator is set to change hands as Trump nominates Heidi Overton, architect of drug-pricing negotiations and vaccine-schedule revisions. Developers and investors are assessing what her confirmation means for approval timelines, pricing pressure, and regulatory predictability.
Full story: https://getbiobrief.com/story/heidi-overton-fda-pharma-regulatory-outlook-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.